Indonesia invites cheap copies of 7 patented HIV drugs

Asia is becoming a danger zone for pharma's intellectual property. On the heels of India's first compulsory licensing move, Indonesia has nixed patent protection on 7 HIV fighters and hepatitis drugs. The move would open the gates to cheap generic rivals, expanding access--and cutting into sales of pharma's brand names.

According to a release from Public Citizen, Indonesian President Susilo Bambang Yudhoyono signed a decree authorizing copycat versions of key HIV drugs, including GlaxoSmithKline's ($GSK) Ziagen (abacavir), Merck's ($MRK) Sustiva (efavirenz), Abbott Laboratories' ($ABT) Kaletra (lopinavir + ritonavir), and Gilead Sciences' ($GILD) Truvada (tenofovir + emtricitabine) and Atripla (tenofovir + emtricitabine + evafirenz).

Compulsory licensing--in which governments order drugmakers to allow copycat versions of their patented drugs--is allowed under the World Trade Organization's rules, provided there's a public-health emergency. As Public Citizen notes, Indonesia's move appears to be the biggest single use of this power since the WTO set the rules in 1995.

Public Citizen figures that Indonesia's move could prompt other countries to do the same. That remains to be seen, but pharma sees its patents under threat around Asia, in markets where companies are hoping for quick growth. India just authorized its first compulsory license--for Natco Pharma's knockoff version of Bayer's cancer drug Nexavar--and drugmakers worry there's more to come. Meanwhile, China just amended its own laws to allow for compulsory licensing.

- read the Public Citizen statement
- get more from Pharmalot

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.